Mersana Therapeutics Stock Current Ratio
| MRSN Stock | USD 6.60 0.25 3.65% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Mersana Therapeutics' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Mersana Therapeutics Company Current Ratio Analysis
Mersana Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Mersana Therapeutics Current Ratio | 3.32 X |
Most of Mersana Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mersana Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Mersana Therapeutics has a Current Ratio of 3.32 times. This is 14.09% higher than that of the Biotechnology sector and 52.57% lower than that of the Health Care industry. The current ratio for all United States stocks is 53.7% lower than that of the firm.
Mersana Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mersana Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mersana Therapeutics could also be used in its relative valuation, which is a method of valuing Mersana Therapeutics by comparing valuation metrics of similar companies.Mersana Therapeutics is currently under evaluation in current ratio category among its peers.
Mersana Fundamentals
| Return On Equity | -5.05 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (2.18) % | ||||
| Operating Margin | (8.90) % | ||||
| Current Valuation | (44.76 M) | ||||
| Shares Outstanding | 4.99 M | ||||
| Shares Owned By Insiders | 1.46 % | ||||
| Shares Owned By Institutions | 71.59 % | ||||
| Number Of Shares Shorted | 7.92 M | ||||
| Price To Earning | (0.98) X | ||||
| Price To Book | 32.03 X | ||||
| Price To Sales | 0.97 X | ||||
| Revenue | 40.5 M | ||||
| Gross Profit | (38.67 M) | ||||
| EBITDA | (63.27 M) | ||||
| Net Income | (69.19 M) | ||||
| Cash And Equivalents | 225.13 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 28.6 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.32 X | ||||
| Book Value Per Share | (6.19) X | ||||
| Cash Flow From Operations | (82.34 M) | ||||
| Short Ratio | 2.62 X | ||||
| Earnings Per Share | (14.75) X | ||||
| Target Price | 123.29 | ||||
| Number Of Employees | 102 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 32.9 M | ||||
| Total Asset | 144.66 M | ||||
| Retained Earnings | (895.55 M) | ||||
| Working Capital | 74.45 M | ||||
| Current Asset | 71.4 M | ||||
| Current Liabilities | 51.32 M | ||||
| Net Asset | 144.66 M |
About Mersana Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mersana Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mersana Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mersana Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Mersana Stock
| 0.63 | DRRX | Durect | PairCorr |
| 0.6 | VERV | Verve Therapeutics Earnings Call This Week | PairCorr |
| 0.46 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.37 | VALN | Valneva SE ADR | PairCorr |
| 0.32 | KG | KING PHARMACEUTICALS INC Symbol Change | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Mersana Therapeutics Piotroski F Score and Mersana Therapeutics Altman Z Score analysis. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.